Haemonetics Corporation

NYSE HAE

Haemonetics Corporation Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 28, 2024: 5.23%

Haemonetics Corporation Return on Assets (ROA) is 5.23% for the Trailing 12 Months (TTM) ending September 28, 2024, a -20.57% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
  • Haemonetics Corporation Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2023 was 6.59%, a 41.23% change year over year.
  • Haemonetics Corporation Return on Assets (ROA) for the Trailing 12 Months (TTM) ending October 01, 2022 was 4.67%, a 151.40% change year over year.
  • Haemonetics Corporation Return on Assets (ROA) for the Trailing 12 Months (TTM) ending October 02, 2021 was 1.86%, a -76.59% change year over year.
  • Haemonetics Corporation Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 26, 2020 was 7.93%, a 44.08% change year over year.
Key data
Date Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio
Market news
Loading...
NYSE: HAE

Haemonetics Corporation

CEO Mr. Christopher A. Simon
IPO Date May 10, 1991
Location United States
Headquarters 125 Summer Street
Employees 3,657
Sector Health Care
Industries
Description

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Similar companies

NVST

Envista Holdings Corp

USD 18.85

-0.74%

ATR

AptarGroup, Inc.

USD 154.61

0.47%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

TFX

Teleflex Incorporated

USD 179.17

0.35%

ATRC

AtriCure, Inc.

USD 34.69

0.87%

WST

West Pharmaceutical Services, Inc.

USD 328.96

-3.13%

RMD

ResMed Inc.

USD 228.83

-0.62%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

AKYA

Akoya Biosciences, Inc.

USD 2.60

-11.26%

StockViz Staff

January 15, 2025

Any question? Send us an email